28430341|t|Prostate-specific antigen increase during dutasteride to indicate the need for prostate biopsy: influence of prostatic inflammation
28430341|a|The aim of this study was to analyze the significance of an increase in total prostate-specific antigen (PSA) serum levels despite dutasteride treatment as a predictor of prostate cancer (PC) at biopsy. We focused our attention on the rate of the first PSA increase and on the influence of prostatic inflammation. From 2011 to 2016, 365 men with a previous negative prostate biopsy and persistent elevated PSA levels received dutasteride treatment. The population was followed for a range of 12-48 months. One hundred twelve cases with a confirmed PSA increase >0.5 ng/ml over the nadir value during the follow-up were included in Group A and underwent a new prostate biopsy. In Group A, the PSA increase was associated with PC at the re-biopsy in 66% of cases. The percentage of PSA reduction after 6 months of treatment was not a significant indicator of the risk for PC. The distribution of inflammatory infiltrates significantly (p<00.01) varied from positive to negative prostate biopsies. The relative risk for PC at biopsy significantly increase d according to PSA level during dutasteride. Treatment with dutasteride can help to analyze PSA kinetic. A persistent prostatic inflammation is a factor able to reduce the performance of PSA kinetic during dutasteride treatment.
28430341	0	25	Prostate-specific antigen	T116,T126,T129	C0138741
28430341	26	34	increase	T169	C0442805
28430341	42	53	dutasteride	T109,T121	C0754659
28430341	79	94	prostate biopsy	T060	C0194804
28430341	109	131	prostatic inflammation	T047	C0033581
28430341	161	168	analyze	T062	C0936012
28430341	192	200	increase	T169	C0442805
28430341	204	254	total prostate-specific antigen (PSA) serum levels	T059	C2123607
28430341	263	274	dutasteride	T109,T121	C0754659
28430341	275	284	treatment	T061	C0087111
28430341	290	299	predictor	T078	C2698872
28430341	303	318	prostate cancer	T191	C0376358
28430341	320	322	PC	T191	C0376358
28430341	327	333	biopsy	T060	C0005558
28430341	367	371	rate	T081	C1521828
28430341	385	388	PSA	T116,T126,T129	C0138741
28430341	385	388	PSA	T116,T126,T129	C0138741
28430341	389	397	increase	T169	C0442805
28430341	422	444	prostatic inflammation	T047	C0033581
28430341	469	472	men	T098	C0025266
28430341	498	513	prostate biopsy	T060	C0194804
28430341	529	537	elevated	T080	C3163633
28430341	538	541	PSA	T116,T126,T129	C0138741
28430341	538	548	PSA levels	T059	C2123607
28430341	558	569	dutasteride	T109,T121	C0754659
28430341	570	579	treatment	T061	C0087111
28430341	585	595	population	T098	C1257890
28430341	680	683	PSA	T116,T126,T129	C0138741
28430341	684	692	increase	T169	C0442805
28430341	736	745	follow-up	T058	C1522577
28430341	791	806	prostate biopsy	T060	C0194804
28430341	824	827	PSA	T116,T126,T129	C0138741
28430341	828	836	increase	T169	C0442805
28430341	841	856	associated with	T080	C0332281
28430341	857	859	PC	T191	C0376358
28430341	867	876	re-biopsy	T060	C0005558
28430341	912	925	PSA reduction	T033	C1096147
28430341	944	953	treatment	T061	C0087111
28430341	976	985	indicator	T201	C0005516
28430341	1002	1004	PC	T191	C0376358
28430341	1026	1050	inflammatory infiltrates	T033	C3887644
28430341	1108	1125	prostate biopsies	T060	C0194804
28430341	1149	1151	PC	T191	C0376358
28430341	1155	1161	biopsy	T060	C0005558
28430341	1176	1184	increase	T169	C0442805
28430341	1200	1203	PSA	T116,T126,T129	C0138741
28430341	1200	1209	PSA level	T059	C2123607
28430341	1217	1228	dutasteride	T109,T121	C0754659
28430341	1230	1239	Treatment	T061	C0087111
28430341	1245	1256	dutasteride	T109,T121	C0754659
28430341	1269	1276	analyze	T062	C0936012
28430341	1277	1280	PSA	T116,T126,T129	C0138741
28430341	1281	1288	kinetic	T070	C0022702
28430341	1303	1325	prostatic inflammation	T047	C0033581
28430341	1372	1375	PSA	T116,T126,T129	C0138741
28430341	1376	1383	kinetic	T070	C0022702
28430341	1391	1402	dutasteride	T109,T121	C0754659
28430341	1403	1412	treatment	T061	C0087111